T-Cell Lymphomas - Pipeline Review, H2 2014

Date: October 30, 2014
Pages: 143
Price:
US$ 2,000.00 US$ 1,500.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: T9BCF807219EN
Leaflet:

Download PDF Leaflet

Summary

Global Markets Direct’s, ‘T-Cell Lymphomas - Pipeline Review, H2 2014’, provides an overview of the T-Cell Lymphomas’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for T-Cell Lymphomas, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Lymphomas and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of T-Cell Lymphomas
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for T-Cell Lymphomas and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the T-Cell Lymphomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the T-Cell Lymphomas pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for T-Cell Lymphomas
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding T-Cell Lymphomas pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
T-Cell Lymphomas Overview
Therapeutics Development
Pipeline Products for T-Cell Lymphomas - Overview
Pipeline Products for T-Cell Lymphomas - Comparative Analysis
T-Cell Lymphomas - Therapeutics under Development by Companies
T-Cell Lymphomas - Therapeutics under Investigation by Universities/Institutes
T-Cell Lymphomas - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
T-Cell Lymphomas - Products under Development by Companies
T-Cell Lymphomas - Products under Investigation by Universities/Institutes
T-Cell Lymphomas - Companies Involved in Therapeutics Development
arGEN-X BV
Bristol-Myers Squibb Company
Celgene Corporation
Cell Medica Limited
Infinity Pharmaceuticals, Inc.
Karyopharm Therapeutics, Inc.
Kyowa Hakko Kirin Co., Ltd.
Nippon Kayaku Co., Ltd.
Novartis AG
Ono Pharmaceutical Co., Ltd.
Onyx Pharmaceuticals, Inc.
Pharma Mar, S.A.
Pharmacyclics, Inc.
Seattle Genetics, Inc.
Sigma-Tau S.p.A.
T-Cell Lymphomas - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ARGX-110 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-906024 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
brentuximab vedotin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
carfilzomib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy to Target CD38 for cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CMD-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs for T-Cell Lymphoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs to Antagonize PDGFR-Beta for T-Cell Lymphomas - Drug Profile
Product Description
Mechanism of Action
R&D Progress
duvelisib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IDD-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lenalidomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
luminespib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mogamulizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nivolumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NK-314 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PCI-34051 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegaspargase - Drug Profile
Product Description
Mechanism of Action
R&D Progress
plitidepsin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
selinexor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
T-Cell Lymphomas - Recent Pipeline Updates
T-Cell Lymphomas - Dormant Projects
T-Cell Lymphomas - Discontinued Products
T-Cell Lymphomas - Product Development Milestones
Featured News & Press Releases
Jun 30, 2014: Reapplication Seeking Approval for Additional Indication for ATL of Mogamulizumab
Feb 10, 2014: Change to Supplemental Application Seeking Approval of Additional Indication for Mogamulizumab
Jan 23, 2014: Infinity Reports Phase 1 Data of IPI-145 at Sixth Annual T-Cell Lymphoma Forum
Jul 19, 2013: Application Seeking Approval for Additional Indication for ATL, PTCL and CTCL of Mogamulizumab
Jun 24, 2013: Infinity Pharma Reports Phase I Data Showing Encouraging Clinical Activity Of IPI-145 Across Broad Range Of Blood Cancers At 12th ICML
Jun 02, 2013: Seattle Genetics Announces Presentation Of Adcetris Clinical Development Programs At ASCO Annual Meeting 2013
Jun 02, 2013: Infinity Pharma Reports Presentation Of Updated Phase I Data Of IPI-145 In Chronic Lymphocytic Leukemia At ASCO Annual Meeting
May 15, 2013: Infinity Pharma Announces Presentation Of Clinical Data On IPI-145 At ASCO 2013 And 12th International Conference On Malignant Lymphoma
Jan 24, 2013: Seattle Genetics And Millennium Initiate Global Phase III Clinical Trial Of Adcetris In Front-line CD30-Expressing Mature T-Cell Lymphoma
Dec 10, 2012: Infinity Pharma Reports IPI-145 Phase I Data Showing Clinical Activity In B-Cell And T-Cell Malignancies At ASH Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for T-Cell Lymphomas, H2 2014
Number of Products under Development for T-Cell Lymphomas - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Late Stage Development, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Products under Development by Companies, H2 2014
Products under Investigation by Universities/Institutes, H2 2014
T-Cell Lymphomas - Pipeline by arGEN-X BV, H2 2014
T-Cell Lymphomas - Pipeline by Bristol-Myers Squibb Company, H2 2014
T-Cell Lymphomas - Pipeline by Celgene Corporation, H2 2014
T-Cell Lymphomas - Pipeline by Cell Medica Limited, H2 2014
T-Cell Lymphomas - Pipeline by Infinity Pharmaceuticals, Inc., H2 2014
T-Cell Lymphomas - Pipeline by Karyopharm Therapeutics, Inc., H2 2014
T-Cell Lymphomas - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2014
T-Cell Lymphomas - Pipeline by Nippon Kayaku Co., Ltd., H2 2014
T-Cell Lymphomas - Pipeline by Novartis AG, H2 2014
T-Cell Lymphomas - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014
T-Cell Lymphomas - Pipeline by Onyx Pharmaceuticals, Inc., H2 2014
T-Cell Lymphomas - Pipeline by Pharma Mar, S.A., H2 2014
T-Cell Lymphomas - Pipeline by Pharmacyclics, Inc., H2 2014
T-Cell Lymphomas - Pipeline by Seattle Genetics, Inc., H2 2014
T-Cell Lymphomas - Pipeline by Sigma-Tau S.p.A., H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
T-Cell Lymphomas Therapeutics - Recent Pipeline Updates, H2 2014
T-Cell Lymphomas - Dormant Projects, H2 2014
T-Cell Lymphomas - Discontinued Products, H2 2014

LIST OF FIGURES

Number of Products under Development for T-Cell Lymphomas, H2 2014
Number of Products under Development for T-Cell Lymphomas - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Late Stage Development, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Products, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Top 10 Targets, H2 2014
Number of Products by Stage and Top 10 Targets, H2 2014
Number of Products by Top 10 Mechanism of Actions, H2 2014
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014
Number of Products by Top 10 Routes of Administration, H2 2014
Number of Products by Stage and Top 10 Routes of Administration, H2 2014
Number of Products by Top 10 Molecule Types, H2 2014
Number of Products by Stage and Top 10 Molecule Types, H2 2014
Skip to top


T-Cell Lymphomas - Pipeline Review, H1 2014 US$ 1,500.00 Apr, 2014 · 132 pages
B - Cell Lymphomas - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages
T - Cell Lymphomas - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages
B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 1066 pages

Ask Your Question

T-Cell Lymphomas - Pipeline Review, H2 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: